JPRN-jRCT2031210491进行中（未招募）3 期
A randomized, Double-Blind, Active-Controlled, Phase 3 Study ofChronocort Compared with Immediate-Release Hydrocortisone Replacement Therapy inParticipants Aged 16 Years and Over with Congenital Adrenal Hyperplasia
Fujii Katsuya0 个研究点目标入组 15 人开始时间: 2021年12月17日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Participant must be aged 16 years or older at the time of signing the informed consent/assent.
- •2. In participants aged <18 years, height velocity must be less than 2 cm/year in the last year and puberty must be completed (Tanner stage V).
- •3. Participants with known classic CAH due to 21-hydroxylase deficiency diagnosed in childhood with documented (at any time) elevated 17-OHP and with or without elevated A4 and currently treated with hydrocortisone, prednisone, prednisolone or dexamethasone (or a combination of the aforementioned glucocorticoids) and on stable glucocorticoid therapy for a minimum of 3 months.
- •4. Participants who are receiving fludrocortisone must be on a documented stable dose for a minimum of 3 months prior to enrollment and must have stable renin levels at screening.
- •5. Male and female participants.
- •Female participants of childbearing potential and all male participants must agree to the use of an accepted method of contraception during the study.
- •A female participant is eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applies:
- •Not a woman of childbearing potential (WOCBP)
- •A WOCBP with a negative pregnancy test at entry into the study.
- •Note: females presenting with oligomenorrhea or amenorrhea who are aged =< 55 years should be considered potentially fertile and therefore should undergo pregnancy testing like all other female participants.
- •6. Capable of giving signed informed consent/assent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
排除标准
- •1. Clinical or biochemical evidence of hepatic or renal disease e.g. creatinine >2 times
- •the upper limit of normal (ULN) or elevated liver function tests (alanine
- •aminotransferase [ALT] or aspartate aminotransferase [AST] >2 times the ULN).
- •2. History of bilateral adrenalectomy.
- •3. History of malignancy (other than basal cell carcinoma successfully treated
- •>26 weeks prior to entry into the study).
- •4. Participants who have type 1 diabetes, receive regular insulin, have uncontrolled diabetes, or have a screening HbA1c greater than 8%.
- •5. Persistent signs of adrenal insufficiency or the participant does not tolerate treatment
- •at the end of the 4-week run-in period.
- •6. Participants with any other significant medical or psychiatric conditions that in the
- •opinion of the Investigator would preclude participation in the study.
- •7. Participants on regular daily inhaled, topical, nasal or oral steroids for any indication
- •other than CAH.
- •8. Co-morbid condition requiring daily administration of a medication or consumption
- •of any material that interferes with the metabolism of glucocorticoids (examples
- •provided at http://medicine.iupui.edu/clinpharm/ddis/clinical-table/).
- •9. Participants who are receiving <10 mg hydrocortisone dose at screening or the
- •hydrocortisone dose equivalent.
- •10. Participants anticipating regular prophylactic use of additional steroids e.g. for
- •strenuous exercise.
- •11. Participation in another clinical study of an investigational or licensed drug or device
- •within the 12 weeks prior to screening.
- •12. Inclusion in any natural history or translational research study that would require
- •evaluation of androgen levels during the study period outside of this protocol's
- •assessments.
- •13. Participants who have previously been exposed to Chronocort in any Diurnal study.
- •14. Participants who routinely work night shifts and so do not sleep during the usual
- •night-time hours.
- •15. Participants, who in the opinion of the Investigator, will be unable to comply with the requirements of the protocol.
- •16. Participants with a known hypersensitivity to any of the components of the Chronocort capsules, the Cortef tablets, or the placebo capsules.
- •17. Participants with congenital galactosemia, malabsorption of glucose and galactose, or who are lactase deficient.
- •18. Participants with a body weight of 45 kg or less.
研究者
相似试验
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitisMedDRA version: 20.0Level: PTClassification code 10072579Term: Granulomatosis with polyangiitisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 20.1Level: PTClassification code 10050894Term: Anti-neutrophil cytoplasmic antibody positive vasculitisSystem Organ Class: 10021428 - Immune system disordersEUCTR2016-001121-14-SEChemoCentryx, Inc.300
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).EUCTR2016-001121-14-ATChemoCentryx, Inc.300
进行中（未招募）
不适用
A Phase 3 Study in Moderate to Severe Rheumatoid ArthritisModerately to severely active rheumatoid arthritisMedDRA version: 17.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-002324-32-SEEli Lilly and Company550
进行中（未招募）
不适用
A phase 3 study in moderate to severe rheumatoid arthritisEUCTR2012-002324-32-ITELI LILLY AND COMPANY550
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitisMedDRA version: 20.0 Level: PT Classification code 10072579 Term: Granulomatosis with polyangiitis System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: PT Classification code 10063344 Term: Microscopic polyangiitis System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.1 Level: PT Classification code 10050894 Term: Anti-neutrophil cytoplasmic antibody positive vasculitis System Organ Class: 10021428 - Immune system disordersEUCTR2016-001121-14-BEChemoCentryx, Inc.300